|
Synonyms: MEDI-4920 | MEDI4920 | VIB 4920 | VIB-4920 | VIB4920
Compound class:
Peptide
Comment: Dazodalibep (VIB4920, formerly MEDI4920) is a fusion protein that is designed to bind to and neutralise the biological actions of the CD40 ligand (CD40L) [2,4]. Structurally dazodalibep contains two tandem human Tn3 tenascin C modules (that bind CD40L [5]) linked to human serum albumin. Previous studies have demonstrated that anti-CD40L antibodies can cause thromboembolic adverse events that arise through antibody Fc-mediated cross-linking between FcγRIIa and CD40L on platelets. The dazodalibep Fc negative fusion protein approach was initiated to mitigate these platelet-related safety issues.
|
| References |
|
1. Aung T. (2026)
Bridging the Gap in Sjögren's Disease: A Comprehensive Review of Unmet Needs, Diagnostic Challenges, and Emerging Therapeutic Strategies. Cureus, 18 (7): e113186. [PMID:42633339] |
|
2. Karnell JL, Albulescu M, Drabic S, Wang L, Moate R, Baca M, Oganesyan V, Gunsior M, Thisted T, Yan L et al.. (2019)
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity. Sci Transl Med, 11 (489). [PMID:31019027] |
|
3. Kivitz A, Wang L, Alevizos I, Gunsior M, Falloon J, Illei G, St Clair EW. (2023)
The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis. RMD Open, 9 (3). [PMID:37541743] |
|
4. Nicholson SM, Casey KA, Gunsior M, Drabic S, Iverson W, Cook H, Scott S, O'Day T, Karanth S, Dixit R et al.. (2020)
The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys. Br J Pharmacol, 177 (5): 1061-1076. [PMID:31648370] |
|
5. Oganesyan V, Ferguson A, Grinberg L, Wang L, Phipps S, Chacko B, Drabic S, Thisted T, Baca M. (2013)
Fibronectin type III domains engineered to bind CD40L: cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of two complexes. Acta Crystallogr Sect F Struct Biol Cryst Commun, 69 (Pt 9): 1045-8. [PMID:23989160] |
|
6. St Clair EW, Baer AN, Ng WF, Noaiseh G, Baldini C, Tarrant TK, Papas A, Devauchelle-Pensec V, Wang L, Xu W et al.. (2024)
CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med, 30 (6): 1583-1592. [PMID:38839899] |
|
7. St Clair EW, Baer AN, Ng WF, Noaiseh G, Tarrant TK, Papas A, Devauchelle-Pensec V, Alevizos I, Baldini C. (2025)
Plain language summary: treatment of Sjögren's disease with dazodalibep. Immunotherapy, 17 (15): 1063-1077. [PMID:41200734] |